2nd Alpine Winter Conference on Medicinal and Synthetic Chemistry

Confirmed Speakers


Keynote Speakers

Expanding the Druggable Genome through Cereblon-Mediated Protein Degradation (KL02)
Dr Lawrence G. HAMANNDr Lawrence G. HAMANN
(BRISTOL-MYERS SQUIBB, San Francisco, United States)

Read more
Necessity is the Mother of Invention: Natural Products and the Chemistry They Inspire (KL01)
Prof. Sarah E. REISMANProf. Sarah E. REISMAN
(CALIFORNIA INSTITUTE OF TECHNOLOGY, Pasadena, United States)
Controlling the Fate and Function of Proteins with Photopharmacology (KL03)
Prof. Dirk TRAUNERProf. Dirk TRAUNER
(NEW YORK UNIVERSITY, New York, United States)

Read more

Accelerating Drug Discovery by Intelligence Augmentation

Exploring an Interface of Synthesis and Data Science (PL18)
Prof. Timothy CERNAKProf. Timothy CERNAK
(UNIVERSITY OF MICHIGAN, Ann Arbor, United States)

Read more
Organic Synthesis on a Computer: Should Medicinal Chemists Care? (PL17)
Prof. Bartosz A. GRZYBOWSKIProf. Bartosz A. GRZYBOWSKI
(ULSAN NATIONAL INSTITUTE OF SCIENCE & TECHNOLOGY, Ulsan, Korea, South)

Read more
Accelerating R&D with Augmented Intelligence (PL19)
Dr Matthias ZENTGRAFDr Matthias ZENTGRAF
(BOEHRINGER INGELHEIM, Biberach an der Riss, Germany)

Read more

Drug Discovery Tales

The Big Impact of Small Changes : Towards Best-in-Class EZH2 and LSD1 Inhibitors (OC08)
Dr Julian LEVELLDr Julian LEVELL
(CONSTELLATION PHARMACEUTICALS, Cambridge, United States)

Read more
Discovery of AZD3458 a Highly Selective PI3Ky Inhibitor: Combining Structure, HDX-MS and Binding Kinetics to Understand the Mode of Action (OC06)
Dr Nils PEMBERTONDr Nils PEMBERTON
(ASTRAZENECA, Mölndal, Sweden)

Read more
The Discovery of a Potent and Orally Bioavailable Macrocyclic Cyclophilin Inhibitor Based on The Structural Simplification of Sanglifehrin A (OC07)
Dr Vicky STEADMANDr Vicky STEADMAN
(EUROFINS DISCOVERY, Essex, United Kingdom)

Read more
Investigating the Chameleonic Properties of RGD Integrin Antagonists for the Treatment of IPF (OC05)
Dr James THOMPSONDr James THOMPSON
(GLAXOSMITHKLINE/UNIVERSITY OF STRATHCLYDE, Stevenage, United Kingdom)

Read more
Discovery of GDC-0334: a potent and orally bioavailable clinical candidate for the inhibition of TRPA1 (OC04)
Dr Vishal VERMADr Vishal VERMA
(GENENTECH, South San Francisco, United States)

Read more

Frontiers of Synthetic Chemistry

A Radical Way to Abeo-Steroids (PL08)
Prof. Philipp HERETSCHProf. Philipp HERETSCH
(FREE UNIVERSITY OF BERLIN, Berlin, Germany)

Read more
New Avenues in Synthesis Enabled by Organic Photoredox Catalysis (PL06)
Prof. David NICEWICZProf. David NICEWICZ
(UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, Chapel Hill, United States)

Read more
Late-Stage Functionalizations (PL07)
Prof. Tobias RITTERProf. Tobias RITTER
(MAX-PLANCK-INSTITUT FÜR KOHLENFORSCHUNG, Mulheim, Germany)

Read more
Break-it-to-Make-it Strategies for Complex Molecule Synthesis (PL05)
Prof. Richmond SARPONGProf. Richmond SARPONG
(UNIVERSITY OF CALIFORNIA, BERKELEY, Berkeley, United States)

Read more

Innovation and Inspiration from Natural Products

Capturing Biological Activity in Natural Product Fragments: Success and Limitations (PL14)
Prof. Karl GADEMANNProf. Karl GADEMANN
(UNIVERSITY OF ZÜRICH, Zürich, Switzerland)

Read more
(De)Construction of Three-Dimensional Molecular Architectures (PL15)
Prof. Thomas MAGAUERProf. Thomas MAGAUER
(UNIVERSITY OF INNSBRUCK, Innsbruck, Austria)
Synthesis of Complex Antiplasmodial Isocyanoterpenes (PL16)
Prof. Christopher VANDERWALProf. Christopher VANDERWAL
(UNIVERSITY OF CALIFORNIA, Irvine, United States)

Read more
Total Synthesis of Chivosazole F (OC03)
Dr Simon WILLIAMSDr Simon WILLIAMS
(SYNGENTA, Stein AG, Switzerland)

Read more

Predictive ADME Sciences: Striking a Balance Between In Silico and Experimental Work?

Structural Attributes Influencing Unbound Tissue Distribution (PL01)
Dr Li DIDr Li DI
(PFIZER, Groton, United States)

Read more
Metabolism of Strained Rings: Tales of the Unexpected (PL02)
Dr Martin HAYESDr Martin HAYES
(ASTRAZENECA, Gothenburg, Sweden)

Read more
Predicting ADME - Reality, Vision or Fantasy? (PL04)
Dr Simone SCHADTDr Simone SCHADT
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

Read more
Leveraging In Silico ADMET Profiles and Ancillary Pharmacology to Influence Prioritization of Hit Series with Higher Probability of Success (PL03)
Dr Falgun SHAHDr Falgun SHAH
(MERCK & CO., West Point, United States)

Read more
Dr Kenichi UMEHARADr Kenichi UMEHARA
(ROCHE PHARMACEUTICAL RESEARCH AND EARLY DEVELOPMENT, Basel, Switzerland)

Read more

Protein Degradation: New Rules for Drug Discovery

Expanding the Druggable Genome through Cereblon-Mediated Protein Degradation (KL02)
Dr Lawrence G. HAMANNDr Lawrence G. HAMANN
(BRISTOL-MYERS SQUIBB, San Francisco, United States)

Read more
Targeted Protein Degradation (PL12)
Prof. Andy PHILLIPSProf. Andy PHILLIPS
(C4 THERAPEUTICS, Watertown, United States)

Read more
Four E3 Ligases, One Target: Towards Novel CDK6 Protacs (OC02)
Dr Christian STEINEBACHDr Christian STEINEBACH
(UNIVERSITY OF BONN, Bonn, Germany)

Read more
Chemical Genomics Approaches to Targeted Protein Degradation (PL13)
Dr Georg WINTERDr Georg WINTER
(RESEARCH CENTER FOR MOLECULAR MEDICINE OF THE AUSTRIAN ACADEMY OF SCIENCES, Vienna, Austria)

Read more

Structure and Biophysics - Companions for Medicinal Chemistry

Membrane Proteins at the SGC – Challenges and Success Stories (PL09)
Dr Katharina DÜRRDr Katharina DÜRR
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

Read more
Discovery of Small Molecule Fascin 1 Inhibitors Using Fragment-Based Drug Discovery (OC01)
Dr Stuart FRANCISDr Stuart FRANCIS
(THE BEATSON INSTITUTE FOR CANCER RESEARCH, Glasgow, United Kingdom)

Read more
The Mechanism of Outer Membrane Protein Insertion by BamA and its Role as a Target for Novel Antibiotic (PL10)
Prof. Sebastian HILLERProf. Sebastian HILLER
(UNIVERSITY OF BASEL, Basel, Switzerland)
Discovery of ABL001, an Allosteric Inhibitor of BCR-ABL: Fragments, Biophysics, Structure and Chemistry (PL11)
Dr Wolfgang JAHNKEDr Wolfgang JAHNKE
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)

Read more

Targeted Delivery - Strategies to Help your Drug Substances get to the Right Place

Using Small Molecules to Engineer and Explore Human Immunity (PL20)
Prof. David SPIEGELProf. David SPIEGEL
(YALE UNIVERSITY, New Haven, United States)

Read more
Intracellular and Tissue Specific Targeting of Therapeutic Modalities (PL22)
Dr Vadim DUDKINDr Vadim DUDKIN
(JANSSEN DISCOVERY SCIENCES, Lansdale, United States)

Read more
SBT6050, a HER2-Directed TLR8 Immunotac™ Therapeutic, is a Potent Human Myeloid Cell Agonist with Tumor-Localized Activity (PL23)
Dr Valerie ODEGARDDr Valerie ODEGARD
(SILVERBACK THERAPEUTICS, Seattle, United States)

Read more
Discovery of Tumor-Targeted TLR7/8 Immune-Stimulating Antibody Conjugates (ISAC): A New Class of Immuno-Oncology Therapeutics (PL21)
Dr Brian SAFINADr Brian SAFINA
(BOLT BIOTHERAPEUTICS, Redwood City, United States)

Read more

EFMC Sponsored Event

Silver Sponsor

Bronze Sponsor

Copyright 2022 LD Organisation srl  |  rue Michel de Ghelderode 33/02 B-1348  Louvain-la-Neuve (Belgium)  Tel. +32 (0)10 45 47 77  |   |  VAT: BE 0464819842
Developed and powered by Antalys